Ensign Peak Advisors Inc Lowers Holdings in Bristol-Myers Squibb (NYSE:BMY)

Ensign Peak Advisors Inc cut its position in Bristol-Myers Squibb (NYSE:BMY) by 1.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,257,479 shares of the biopharmaceutical company’s stock after selling 42,230 shares during the quarter. Ensign Peak Advisors Inc owned about 0.11% of Bristol-Myers Squibb worth $93,753,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the company. Summit Trail Advisors LLC raised its position in shares of Bristol-Myers Squibb by 197.2% during the 2nd quarter. Summit Trail Advisors LLC now owns 48,579 shares of the biopharmaceutical company’s stock valued at $2,017,000 after buying an additional 32,236 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Bristol-Myers Squibb by 0.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 55,336 shares of the biopharmaceutical company’s stock valued at $2,298,000 after buying an additional 338 shares in the last quarter. Skandinaviska Enskilda Banken AB publ raised its position in shares of Bristol-Myers Squibb by 217.5% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 1,365,284 shares of the biopharmaceutical company’s stock valued at $56,700,000 after buying an additional 935,273 shares in the last quarter. AE Wealth Management LLC raised its position in shares of Bristol-Myers Squibb by 17.2% during the 2nd quarter. AE Wealth Management LLC now owns 108,803 shares of the biopharmaceutical company’s stock valued at $4,519,000 after buying an additional 15,934 shares in the last quarter. Finally, Bridges Investment Management Inc. raised its position in shares of Bristol-Myers Squibb by 15.6% during the 2nd quarter. Bridges Investment Management Inc. now owns 14,600 shares of the biopharmaceutical company’s stock valued at $606,000 after buying an additional 1,971 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Performance

NYSE:BMY opened at $49.38 on Friday. The stock has a market cap of $100.10 billion, a P/E ratio of -15.93, a price-to-earnings-growth ratio of 12.59 and a beta of 0.46. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86. The firm’s fifty day simple moving average is $47.68 and its 200 day simple moving average is $46.49. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $59.46.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.64 by $0.43. The business had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.75 earnings per share. As a group, research analysts predict that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.86%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Analyst Ratings Changes

Several analysts have recently weighed in on BMY shares. Jefferies Financial Group raised their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research report on Wednesday, August 28th. Cantor Fitzgerald restated a “neutral” rating and set a $50.00 price target on shares of Bristol-Myers Squibb in a research report on Monday, September 16th. Barclays raised their price objective on Bristol-Myers Squibb from $41.00 to $42.00 and gave the company an “underweight” rating in a research note on Thursday, August 22nd. TD Cowen boosted their target price on Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a “hold” rating in a research note on Monday, August 12th. Finally, StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $55.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.